In order to view some of the files linked to this page, you may need to download them and open them using Adobe Acrobat. The contents of this site are for private use only and are not to be distributed or reproduced without the express written consent of the copyright holders.


David Riese's CV - PubMed Search - Google Scholar Profile - NCBI MyBibliography - ORCID Profile


As an Undergraduate Research Fellow (1986); Oak Ridge National Laboratory, Biology Division; RC Mann, JK Selkirk and BK Mansfield, Advisors ------------->

BC1. JK Selkirk, BK Mansfield, DJ Riese II, A Nikbakht, and RC Mann. "Two-dimensional gel electrophoresis of cytoplasmic proteins in control and transformed 10T1/2 and CVP cells after benzo[a]pyrene treatment." In: Multilevel health effects research: From Molecules to Man: Proceedings of the Twenty-Seventh Hanford Life Sciences Symposium, JF Park and RA Pelroy, eds. Batelle Press, Columbus, OH (1988). ISBN: 09-3547-055-7.

3. JK Selkirk, BK Mansfield, DJ Riese, A Nikbakht, and RC Mann. Two-dimensional gel electrophoretic comparison of cytoplasmic proteins in C3H10T1/2 cells, a chemically-transformed 10T1/2 line, and a transformation resistant C3H mouse ventral prostate cell line. Appl Theoret Electrophoresis 2: 43-51 (1991). PMID: 1932209.

As a Graduate Student (1987-1993); Yale University School of Medicine, Department of Genetics; Professor Daniel DiMaio, Advisor

A recombinant papovavirus that expresses the BPV E2 gene inhibits (B) clonigenic proliferation and (D) anchorage-independent proliferation of HeLa cervical cancer cells. Mock-infected cells are shown in (A) and (C). From Hwang, et al., J Virology 67: 3720-3729 (1993).

All publications as a graduate student ----------------------->

1. DJ Riese II, J Settleman, K Neary, and D DiMaio. Bovine papillomavirus E2 repressor mutant displays a high-copy-number phenotype and enhanced transforming activity. J Virology 64: 944-949 (1990). PMID: 2153255. Personal Copy

2. C Leptak, S Ramon y Cajal, R Kulke, BH Horwitz, DJ Riese II, GP Dotto, and D DiMaio. Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16. J Virology 65: 7078-7083 (1991). PMID: 1658398. Personal Copy

4. ES Hwang, DJ Riese II, J Settleman, LA Nilson, J Honig, S Flynn, and D DiMaio. Inhibition of cervical carcinoma cell line proliferation by the introduction of a bovine papillomavirus regulatory gene. J Virology 67: 3720-3729 (1993). PMID: 8389903. Personal Copy. Figure 4.

6. DJ Riese II and D DiMaio. An intact PDGF signaling pathway is required for efficient growth transformation of mouse C127 cells by the bovine papillomavirus E5 protein. Oncogene 10: 1431-1439 (1995). PMID: 7731695. Personal Copy.

BC2. LA Nilson, LM Petti, D Drummond-Barbosa, DJ Riese II, ES Hwang, T Nottoli, C Henningson Jr, GW Polack, DM Kegler-Ebo, and D DiMaio. “The role of the cellular platelet-derived growth factor receptor in cell transformation by the bovine papillomavirus E5 protein.” In: Current Developments in Animal Virology, S Jameel and EK Wagner, eds. Science Publishers (1996). ISBN: 18-8610-661-4.

As a Postdoctoral Fellow (1993-1997); Yale University School of Medicine, Department of Pathology; Professor David F. Stern, Advisor

The neuregulin2 (NRG2) gene encodes an EGF-like protein that is a ligand for ERBB3 and ERBB4, but not for EGFR or ERBB2. From Huang, et al., Nature 387 (6632): 509-512 (1997).

All publications as a postdoc ----------------------->

5. DJ Riese II, TM van Raaij, GD Plowman, GC Andrews, and DF Stern. The cellular response to neuregulins is governed by complex interactions of the erbB receptor family. Mol Cell Biol 15: 5770-5776 (1995). PMID: 7565730. Personal Copy

7. DJ Riese II, Y Bermingham, TM van Raaij, S Buckley, GD Plowman, and DF Stern. Betacellulin activates the epidermal growth factor receptor and erbB4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 12:345-353 (1996). PMID: 8570211.

8. DJ Riese II, ED Kim, K Elenius, S Buckley, M Klagsbrun, GD Plowman, and DF Stern. The epidermal growth factor receptor couples transforming growth factor alpha, amphiregulin, and heparin-binding EGF-like growth factor to neu, erbB3, and erbB4. J Biol Chem 271: 20047-20052 (1996). PMID: 8702723. Personal Copy

9. S Kannan, M De Santis, M Lohmeyer, DJ Riese II, GH Smith, N Hynes, M Seno, R Brandt, C Bianco, G Persico, N Kenney, N Normanno, I Martinez-Lacaci, F Ciardiello, DF Stern, WJ Gullick, and D Salomon. Cripto enhances the tyrosine phosphorylation of shc and activates map-kinase in mammary epithelial cells. J Biol Chem 272: 3330-3335 (1997). PMID: 9013573. Personal Copy

10. H Chang, DJ Riese II, W Gilbert, DF Stern, and UJ McMahan. Ligands for erbB family receptors encoded by a newly characterized neuregulin-like gene. Nature 387: 509-512 (1997). PMID: 9168114. Personal Copy. Figure 1. Figure 4b.

The constitutively-dimerized and -active Q646C mutant of ERBB4 inhibits clonigenic proliferation of the DU-145 human prostate tumor cell line. From Williams, et al., Cancer Lett 192 (01): 67-74 (2003).

The ERBB4 Q646C mutant inhibits clonigenic proliferation of the MCF7 human mammary tumor cell line and of the MCF10A human normal mammary epithelial cell line. The latter effect is due to inhibition of cell proliferation rather than induction of cell death. From Pitfield, et al., Oncol Res 16 (04): 179-193 (2006).

The Q43L mutation converts the ERBB4 full agonist NRG2beta to a partial agonist, whereas the corresponding L43Q mutation increases the efficacy of the ERBB4 partial agonist NRG2alpha. From Wilson, et al., Biochem Biophys Res Commun 364 (02): 351-357 (2007).

Different members of the EGF family of peptide hormones exhibit distinct patterns of binding to ERBB family receptors. From Wilson, et al., Pharmacol Ther 122 (01): 1-8 (2009).

The epidermal growth factor receptor may couple moderate alcohol consumption to increased breast cancer risk. From Mill, et al., Breast Cancer – Targets and Therapy (London) 1: 31-38 (2009).

All publications as a Purdue University faculty member ----------------------->

11. DJ Riese II and DF Stern. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20: 41-48 (1998). PMID: 9504046. Personal Copy

12. DJ Riese II, T Komurasaki, GD Plowman, and DF Stern. Activation of ErbB4 by the bifunctional EGF family hormone epiregulin is regulated by ErbB2. J Biol Chem 273: 11288-11294 (1998). PMID: 9556621. Personal Copy

13. C Sweeney, C Lai, DJ Riese II, AJ Diamonti, LC Cantley, and KL Carraway III. Ligand discrimination in signaling through an ErbB4 receptor homodimer. J Biol Chem 275: 19803-19807 (2000). PMID: 10867024. Personal Copy

14. F Mu, SL Coffing, DJ Riese II, RL Geahlen, P Verdier-Pinard, E Hamel, J Johnson, and M Cushman. Design, synthesis, and biological evaluation of a series of Lavendustin A analogs which inhibit EGFR and Lck tyrosine kinases, as well as tubulin polymerization. J Med Chem 44: 441-452 (2001). PMID: 11462983. Personal Copy

15. K Feroz, EE Williams, and DJ Riese II. ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell Signal 14: 793-798 (2002). PMID: 12034361. Personal Copy

16. DJ Penington, I Bryant, and DJ Riese II. Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities. Cell Growth Differ 13: 247-256 (2002). PMID: 12114214. Personal Copy

17. SS Hobbs, SL Coffing, ATD Le, EM Cameron, EE Williams, M Andrew, EN Blommel, RP Hammer, H Chang, and DJ Riese II. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 21: 8442-8452 (2002). PMID: 12466964. Personal Copy

18. J Walker-Daniels, DJ Riese II, and MS Kinch. c-Cbl dependent EphA2 protein degradation is induced by ligand binding. Mol Cancer Res 1: 79-87 (2002). PMID: 12496371. Personal Copy

19. EE Williams, LJ Trout, RM Gallo, SE Pitfield, DJ Penington, I Bryant, and DJ Riese II. A constitutively-active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 192: 67-74 (2003). PMID: 12637154. Personal Copy. Figure 1.

20. SS Hobbs, EM Cameron, RP Hammer, ATD Le, RM Gallo, EN Blommel, SL Coffing, and DJ Riese II. Five carboxyl-terminal residues of Neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 23: 883-894 (2004). PMID: 14661053. Personal Copy

21. JL Gilmore and DJ Riese II. secErbB4-26/549 antagonizes ligand-induced ErbB4 tyrosine phosphorylation. Oncol Res 14: 589-602 (2004). PMID: 15667000. Personal Copy

22. HF VanBrocklin, JK Lim, SL Coffing, DL Hom, K Negash, MY Ono, SM Hanrahan, SE Taylor, JL Gilmore, I Bryant, and DJ Riese II. Anilino-dialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes. J Med Chem 48: 7445-7456 (2005). PMID: 16279804. Personal Copy

23. SS Hobbs, RM Gallo, and DJ Riese II. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta. Growth Factors 23: 273-283 (2005). PMID: 16338790. Personal Copy

24. JL Gilmore, RM Gallo, and DJ Riese II. The EGFR-S442F mutant displays increased affinity for Neuregulin2-beta and agonist-independent coupling to downstream signaling events. Biochem J 396: 79-88 (2006). PMID: 16445385. Personal Copy

25. RM Gallo, I Bryant, R Fry, EE Williams, and DJ Riese II. Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines. Biochem Biophys Res Com 349: 372-382 (2006). PMID: 16934755. Personal Copy

26. SE Pitfield, I Bryant, DJ Penington, G Park, and DJ Riese II. Phosphorylation of ErbB4 on tyrosine 1056 is critical for ErbB4 coupling to inhibition of colony formation by human mammary cell lines. Oncol Res 16: 179-193 (2006). PMID: 17120616. Personal Copy. Figure 1. Figure 6. Table 3.

27. DJ Riese II, RM Gallo, and J Settleman. Mutational activation of ErbB receptor tyrosine kinases: Insights into mechanisms of signal transduction and tumorigenesis. Bioessays 29: 558-565 (2007). PMID: 17508401. Personal Copy

28. N Godin-Heymann, I Bryant, MN Rivera, L Ulkus, DW Bell, DJ Riese II, J Settleman, and DA Haber. Oncogenic activity of EGFR kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res 67: 7319-7326 (2007). PMID: 17671201. Personal Copy

BC3. RM Gallo and DJ Riese II. "Activating Mutations of ErbB Family Receptor Tyrosine Kinases." In: Recent Progress in Cancer Research, C.K. Tang, ed. Transworld Research Network, Kerala, India (2007). ISBN: 81-7895-253-X. Personal Copy

29. JL Gilmore, JA Scott, Z Bouizar, A Robling, SE Pitfield, DJ Riese II, and J Foley. Amphiregulin-EGFR signaling regulates PTHrP gene expression in breast cancer cells. Breast Cancer Res Treat 110: 493-505 (2008). PMID: 17882547. Personal Copy

30. KJ Wilson, CP Mill, EM Cameron, SS Hobbs, RP Hammer, and DJ Riese II. Interconversion of Neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Com 364: 351-357 (2007). PMID: 17945187. Personal Copy. Figure 2c. Figure 4b.

31. RM Gallo and DJ Riese II. The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine 1056. Growth Factors 25: 329-333 (2007). PMID: 18236211. Personal Copy

32. T Frogne, RV Benjaminsen, K Sonne-Hansen, BS Sorensen, E Nexo, A-V Laenkholm, LM Rasmussen, DJ Riese II, P de Cremoux, J Stenvang, and AE Lykkesfeldt. Activation of ErbB3, EGFR, and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 114: 263-275 (2009). PMID: 18409071. Personal Copy

33. SM Rothenberg, JA Engelman, S Le, DJ Riese II, DA Haber, and J Settleman. Modeling oncogene addiction with RNA interference. Proc Natl Acad Sci USA 105: 12480-12484 (2008). PMID: 18711136. Personal Copy

34. NE Willmarth, A Baillo, ML Dziubinski, K Wilson, DJ Riese II, and SP Ethier. Altered EGFR localization and degradation in human breast cancer cells with an amphiregulin/EGFR autocrine loop. Cell Signal 21: 212-219 (2009). PMID: 18951974. Personal Copy

35. JA Przybyla, JP Cue, BR Chemel, KJ Hsu, DJ Riese II, JD McCorvy, JA Chester, DE Nichols, and VJ Watts. Comparison of the enantiomers of (±)-doxanthrine, a high efficacy full dopamine D1 receptor agonist, and a reversal of enantioselectivity at D1 versus alpha2C adrenergic receptors. Eur Neuropsychopharmacol 19: 138-146 (2009). PMID: 19028082. Personal Copy

36. KJ Wilson, JL Gilmore, J Foley, MA Lemmon, and DJ Riese II. Functional selectivity of EGF Family Peptide Growth Factors: Implications for Cancer. Pharmacol Ther 122: 1-8 (2009). PMID: 19135477. Personal Copy. Figure 2.

37. CP Mill, JA Chester, and DJ Riese II. The epidermal growth factor receptor may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer – Targets and Therapy (London) 1: 31-38 (2009). PMID: 20485537. Personal Copy. Figure 1.

38. BG Coon, D Mukherjee, CB Hanna, DJ Riese II, M Lowe, and RC Aguilar. Lowe syndrome patient fibroblasts display Ocr11-specific cell migration defects that cannot be rescued by the homologous Inpp5b phosphatase. Hum Mol Gen 18: 4478-4491 (2009). PMID: 19700499. Personal Copy

39. JL Gilmore, RM Gonterman, K Menon, G Lorch, DJ Riese II, A Robling, and J Foley. Reconstitution of amphiregulin-EGFR signaling in lung squamous carcinomas activates PTHrP gene expression and cancer-mediated diseases of the bone. Mol Cancer Res 7: 1714-1728 (2009). PMID: 19825997. Personal Copy

As Professor (2010-present); Associate Dean for Research and Graduate Programs (2010-2018); Auburn University Harrison School of Pharmacy, Department of Drug Discovery and Development

Amphiregulin (AREG) stimulation of EGFR signaling in breast tumor cells enables bone metastasis (colonization), in part via PTHrP expression. From Foley, et al., Sem Cell Dev Biol 21: 951-960 (2010).

The ERBB4 Q646C mutant inhibits clonigenic proliferation of the MIA-PaCa-2 human pancreatic tumor cell line. In contrast, expression of wild-type ERBB4 enables the ERBB4 agonist NRG1beta to stimulate anchorage-independent proliferation. From Mill, et al., Exp Cell Res 317: 392-404 (2011).

Automated laser ablation and photomicroscopy facilitates the analysis of tumor cell motility. From Zordan, et al., Cytometry A 79A (03): 227-232 (2011).

In MCF7 human breast tumor cells, silencing either ERBB2 or ERBB4 inhibits stimulation of motility by the ERBB4 agonist NRG2beta. From Mill, et al., Genes & Cancer 2 (08): 792-804 (2011).

Amphiregulin (AR) exhibits greater efficacy at the EGF receptor than does EGF. Disruption of c-Cbl binding to EGFR at Tyr1945 permits EGF to function as a full agonist at EGFR. From Wilson, et al., Growth Factors 30: 107-116 (2012).

The Q43L mutant of the ERBB4 full agonist NRG2beta antagonizes the agonistic activity of wild-type NRG2beta. From Wilson, et al., Biochem J 443: 133-144 (2012).

EGFR signaling stimulates PTHrP expression via activation of the PLCgamma signaling pathway and the Ras signaling pathway. From Foley, et al., Odontology 100: 109-129 (2012).

Epiregulin stimulation of EGF receptor (ErbB receptor) signaling is regulated by cleavage of membrane-bound pro-Epiregulin. From Riese and Cullum, Sem Cell Dev Biol 28 (01): 49-56 (2014).

The CXCL12/CXCR4/CXCR7 signaling network is coupled to a plethora of signaling effectors and biological responses. From Shi, et al., Front Pharmacol 11: 574667 (2020).

Prioritized small molecule candidate inhibitors of ERBB4 signaling. From Cullum, et al., PLOS One 15 (12): e0243901 (2020).

Proposed role for ERBB4 homodimers and ERBB4-EGFR or ERBB4-ERBB2 heterodimers in human malignancies. From Lucas, et al., Pharm Rev 74 (01): 18-47 (2022).

All publications as an Auburn University faculty member ----------------------->

40. J Foley, NK Nickerson, S Nam, KT Allen, JL Gilmore, KP Nephew, and DJ Riese II. EGFR signaling in breast cancer: Bad to the bone? Sem Cell Dev Biol 21: 951-960 (2010). PMID: 20813200. Personal Copy. Figure 2.

41. CP Mill, K Gettinger, and DJ Riese II. Ligand stimulation of ErbB4 and a constitutively-active ErbB4 mutant result in different biological responses in human pancreatic tumor cell lines. Exp Cell Res 317: 392-404 (2011). PMID: 21110957. Personal Copy. Figure 6. Figure 7.

42. DJ Riese II. Ligand-based receptor tyrosine kinase partial agonists: New paradigm for cancer drug discovery? Expert Opin Drug Disc 6: 185-193 (2011). PMID: 21532939. Personal Copy

43. MD Zordan, CP Mill, DJ Riese II, and JF Leary. A high-throughput, interactive imaging, bright-field wound healing assay. Cytometry A 79A: 227-232 (2011). PMID: 22045642. Personal Copy. Figure 1.

BC4. NK Nickerson, JL Gilmore, KT Allen, DJ Riese II, KP Nephew and J Foley. "EGFR Ligand-Specific Signaling in Breast Cancer Metastasis: Recurring Developmental Themes." Breast Cancer – Carcinogenesis, Cell Growth, and Signalling Pathways, Mehmet Gunduz and Esra Gunduz, eds. Intech Publishing, Rijeka, Croatia (2011). ISBN: 978-953-307-714-7. Personal Copy

44. CP Mill, MD Zordan, SM Rothenberg, J Settleman, JF Leary, and DJ Riese II. ErbB2 is necessary for ErbB4 ligands to stimulate oncogenic activities in models of human breast cancer. Genes & Cancer 2: 792-804 (2011). PMID: 22393464. Personal Copy. Figure 2.

45. KJ Wilson, CP Mill, S Lambert, J Buchman, TR Wilson, V Hernandez-Gordillo, RM Gallo, LMC Ades, J Settleman, and DJ Riese II. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 30: 107-116 (2012). PMID: 22260327. Personal Copy. Figure 3b.

46. KJ Wilson, CP Mill, RM Gallo, EM Cameron, H VanBrocklin, J Settleman, and DJ Riese II. The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist. Biochem J 443: 133-144 (2012). PMID: 22216880. Personal Copy. Figure 1d. Figure 1f.

47. J Foley, NK Nickerson, DJ Riese, PC Hollenhorst, G. Lorch, AM Foley. At the crossroads: EGFR and PTHrP signaling in cancer-mediated diseases of the bone. Odontology 100: 109-129 (2012). PMID: 22684584. Personal Copy. Figure 3.

48. NK Nickerson, CP Mill, HJ Wu, DJ Riese II, and J Foley. Autocrine-derived epidermal growth factor receptor ligands contribute to recruitment of tumor-associated macrophage and growth of basal breast cancer cells in vivo. Oncol Res 20:303-17 (2013). PMID: 23879171. Personal Copy

49. RE Allen, J Copeland, AS Franks, R Karimi, M McCollum, DJ Riese II, and AYF Lin. Team-based learning in US colleges and schools of pharmacy. Am J Pharm Ed 77 (06): 115 (2013). PMID: 23966718. Personal Copy

50. RM Gallo, IN Bryant, CP Mill, S Kaverman, and DJ Riese 2nd. Multiple functional motifs are required for the tumor suppressor activity of a constitutively-active ErbB4 mutant. J Cancer Res Ther Oncol 1 (01): 104 (2013). PMID: 24791013. Full Text. Personal Copy

51. DJ Riese II and RL Cullum. Epiregulin: Roles in Normal Physiology and Cancer. Sem Cell Dev Biol 28 (01): 49-56 (2014). PMID: 24631357. Personal Copy. Figure 1.

52. S Kanthala, CP Mill, DJ Riese II, M Jaiswal, and S Jois. Expression and purification of HER2 extracellular domain proteins in Schneider2 insect cells. Protein Expr Purif 125 (01): 26-33 (2016). PMID: 26363121. Personal Copy

53. FML Kabir, P DeInnocentes, P Agarwal, CP Mill, DJ Riese II, and RC Bird. Estrogen Receptor-alpha, Progesterone Receptor and c-erbB/HER-Family Receptor mRNA Detection and Phenotype Analysis in Spontaneous Canine Models of Breast Cancer. J Vet Sci 18 (02): 149-158 (2017). PMID: 27515268. Personal Copy

54. Y Shi, DJ Riese II, and J. Shen. The Role of the C-X-C Motif Chemokine Ligand 12/C-X-C Chemokine Receptor Type 4/C-X-C Chemokine Receptor Type 7 Chemokine Axis in Cancer. Front Pharmacol 11: 574667 (2020). PMID: 33363463. Personal Copy. Figure 1.

55. RL Cullum, LM Lucas, JI Senfeld, JT Piazza, LT Neel, K Whig, L Zhai, MH Harris, CC Rael, DC Taylor, LJ Cook, DP Kaufmann, CP Mill, MA Jacobi, FT Smith, M Suto, R Bostwick, RB Gupta, AE David, and DJ Riese II. Development and application of high-throughput screens for the discovery of compounds that disrupt ErbB4 signaling: Candidate cancer therapeutics. PLOS One 15: (12) e0243901 (2020). PMID: 33378376. Personal Copy. Figure 7.

56. RL Cullum and DJ Riese II. The stimulated random assignment of missense mutations throughout a gene can determine whether missense mutations found in that gene in a population of tumor genomes are non-randomly distributed. (2021). DOI.

57. LM Lucas, V Dwivedi, J Senfeld, RL Cullum, CP Mill, JT Piazza, IN Bryant, LJ Cook, ST Miller, C Kelley, E Knerr, J Markham, D Kaufmann, M Jacobi, J Shen, and DJ Riese II. The yin and yang of ERBB4: Tumor suppressor and oncogene. Pharm Rev 74 (01): 18-47 (2022). PMID: 34987087. Personal Copy. DOI. Figure 7.

58. LM Lucas, RL Cullum, V Dwivedi, JA Markham, JN Woggerman, CM Kelley, EL Knerr, LJ Cook, HC Lucas II, DS Waits, TM Ghosh, KM Halanych, RB Gupta, and DJ Riese II. ERBB4 drives the proliferation of BRAF WT melanoma cell lines. medRxiv, 2022. Personal Copy. DOI.

59. LM Lucas, RL Cullum, JA Markham, JN Woggerman, V Dwivedi, RH Mohamedelhassan, LJ Cook, CM Kelley, EL Knerr, DP Kaufmann, MA Jacobi, DC Taylor, CC Rael, DS Waits, TM Ghosh, KM Halanych, RB Gupta and DJ Riese II. ERBB4 mutant alleles may drive BRAF WT melanomas. medRxiv, 2022. Personal Copy. DOI.